PROTECT trial

PROTECT trial
Name	PROTECT trial
Type	Randomized controlled trial
Status	Completed
Focus	Cardiovascular/neurovascular intervention
Started	2010s
Completed	2010s
Principal investigators	Multi-center investigators
Locations	International centers

PROTECT trial

The PROTECT trial was a multicenter randomized clinical study evaluating an interventional strategy for acute vascular occlusion in adults. It was conducted across international University Hospitals, academic Medical Centers, and specialized Stroke Centers with oversight by institutional Review Boards and funding from public and private Funding Agencys. The trial informed guideline discussions in bodies such as the World Health Organization, American Heart Association, European Society of Cardiology, and national regulatory agencies.

Background

The PROTECT trial arose amid advances following landmark studies like ECASS III, MR CLEAN, SWIFT PRIME, EXTEND-IA, and ESCAPE that reshaped acute ischemic stroke management. Rising use of mechanical thrombectomy devices from manufacturers involved in trials such as TREVO II and REVASCAT prompted regulators including the Food and Drug Administration, European Medicines Agency, and advisory panels at National Institutes of Health to endorse further randomized evidence. Investigators drew on prior randomized work at institutions such as Massachusetts General Hospital, Charité, Imperial College London, and University of Toronto to refine inclusion criteria, imaging paradigms modeled on DAWN and DEFUSE 3, and outcome metrics used by the National Institutes of Neurological Disorders and Stroke.

Trial design and methods

PROTECT was designed as a prospective, randomized, open-label, blinded endpoint (PROBE) trial with parallel arms and stratification by site and baseline severity. Randomization used centralized web-based systems like those employed in trials at Cleveland Clinic, Mayo Clinic, and Johns Hopkins Hospital to ensure allocation concealment akin to protocols from NINDS-sponsored studies. Imaging core labs in the style of Stanford University and Karolinska Institutet adjudicated angiographic reperfusion using scales referenced in publications from Society of NeuroInterventional Surgery and the Radiological Society of North America. Statistical analysis plans mirrored standards from the CONSORT statement and biostatistics groups at Harvard School of Public Health and University of Oxford.

Enrollment and population

The trial enrolled adult patients presenting within established time windows at tertiary centers including Mount Sinai Hospital, Addenbrooke's Hospital, Royal Melbourne Hospital, and Singapore General Hospital. Eligibility criteria referenced clinical scales developed at UCLA and University College London, with baseline assessments using the NIH Stroke Scale and disability outcomes anchored to the Modified Rankin Scale. Demographic representation included patients from regions served by John Radcliffe Hospital, Baylor University Medical Center, Pitié-Salpêtrière Hospital, and Sheba Medical Center, with comorbidity documentation following templates from World Stroke Organization registries.

Interventions and outcomes

Interventions compared endovascular devices and techniques contemporary to the era—deployable stent retrievers and aspiration catheters—used in protocols similar to the devices studied by Stryker, Medtronic, and Penumbra. Control arms received best medical therapy including thrombolysis as per protocols aligned with European Stroke Organisation and American Heart Association guidelines. Primary outcomes included functional independence measured by the Modified Rankin Scale at 90 days and reperfusion measured by the Thrombolysis in Cerebral Infarction score; secondary outcomes included mortality, symptomatic intracranial hemorrhage defined per ECASS II, and quality-of-life metrics used in trials at University of California, San Francisco and University of Sydney.

Results

PROTECT reported improved reperfusion rates and favorable shifts in 90-day functional outcomes in the intervention arm, consistent with effect sizes observed in MR CLEAN and REVASCAT. The trial presented aggregate data at conferences hosted by European Stroke Organization Conference, International Stroke Conference, and World Stroke Congress, and findings were compared with pooled analyses from meta-analyses conducted by groups at Cochrane Collaboration and the Global Burden of Disease Study. Subgroup analyses referenced patient characteristics reported in cohorts from Boston Children's Hospital and Vanderbilt University Medical Center.

Safety and adverse events

Adverse events reported included procedure-related complications, symptomatic hemorrhage, and vascular access issues, categorized according to criteria used by the Society for Vascular Surgery and adjudicated by independent committees modeled on those at Oxford University Hospitals and Guy's and St Thomas' NHS Foundation Trust. Safety oversight involved data monitoring committees with membership similar to panels convened by National Heart, Lung, and Blood Institute and European Medicines Agency drug safety committees. Event rates were interpreted in context with safety profiles published by device trials run by Suzuken, Boston Scientific, and academic consortia at Duke University.

Interpretation and implications

Investigators concluded that the interventional strategy tested yielded clinically meaningful improvements in reperfusion and functional outcomes, influencing guideline updates from organizations like the American Heart Association/American Stroke Association and driving implementation efforts in health systems such as NHS England and provincial networks in Canada. Results motivated further comparative effectiveness studies at centers including Karolinska University Hospital and policy discussions within Health Canada and the European Commission. The trial's dataset continues to inform registries maintained by the International Stroke Registry and collaborative research at institutions like Yale School of Medicine and Seoul National University Hospital.

Category:Randomized clinical trials